The market valuation of TRANSTHERA-B (02617) has plummeted from a historical peak of HK$270 billion to approximately HK$4.1 billion. On June 23rd, the company entered the second phase of a post-IPO lock-up expiration, with its share price closing at HK$11.25, marking a single-day drop of 59.71%. The following day saw an additional decline of 11.11%. This represents a drawdown of over 98% from its all-time high. Looking back to September 2025, the stock price surged 557% within a single week, briefly propelling its market cap to HK$270 billion. At that time, the company had no commercialized products and lacked stable revenue. This irrational surge was essentially the result of multiple factors converging, including index rebalancing triggering passive ETF buying, concentrated inflows from southbound capital, and an extremely low free float. Now, with the lock-up expiration concluded, the market has swung to the opposite extreme. Despite having the same pipeline and team, the company's valuation has collapsed from HK$270 billion to HK$41 billion. These two extremes and deviations suggest the market's pricing has never truly anchored to the company's intrinsic value.
The lock-up expiration merely altered the shareholder structure; the fundamental business of TRANSTHERA-B has not undergone substantive change. In response to the market volatility, the company's board swiftly acted, issuing a voluntary announcement on June 28th. It declared an intention to repurchase H-shares on the open market, with a total amount capped at RMB 100 million or the equivalent in Hong Kong dollars. This move demonstrates the board's recognition of the company's intrinsic value and confidence in its product pipeline. The day after the announcement, the share price responded positively, surging over 50% intraday and closing up 39.78%.
A Striking Contrast in Capability
As the bubble deflates and sentiment calms, a stark contrast emerges upon re-examining this company whose valuation was slashed from HK$270 billion to HK$41 billion. How can this small biotech firm, with just over 100 employees, dare to simultaneously advance an international multi-center Phase III clinical trial across over a hundred sites in major regions including the US and Europe?
Addressing an Unmet Need in a Challenging Field
Could a 100-person team manage an international multi-center Phase III trial? Within the traditional logic of Big Pharma, it seems impossible. However, TRANSTHERA-B has chosen a different path: focusing on First-in-Class therapies, tackling what others cannot. This is not mere audacity but is based on a globally unique competitive position and a vast, unmet clinical need. Cholangiocarcinoma (CCA) is a rare yet highly aggressive malignancy. The global CCA drug market reached $2 billion in 2024 and is projected to grow to $3.2 billion by 2027. Approximately 25.2% of CCA patients harbor FGFR alterations, making FGFR inhibitors an important second-line treatment option. However, a harsh reality persists: nearly all patients receiving FGFR inhibitor treatment eventually develop acquired resistance. Once resistance occurs, subsequent treatment options are extremely limited, leaving patients in a dire "no treatment available" situation.
This is not an overlooked field. On the contrary, pharmaceutical giants once rushed in. Relay Therapeutics' RLY-4008 initially showed promising early clinical data, but due to factors including slower-than-expected clinical progress, pressure from the Inflation Reduction Act (IRA), and a shift in corporate strategic priorities, the company ultimately withdrew. The high barriers of the赛道 have similarly thwarted other attempts.
The Significance of a "Globally Unique" Asset
As competitors retreated, TRANSTHERA-B's Tingenitinib (TT-00420) accelerated forward. In the CCA treatment landscape, Tingenitinib is the world's first and only investigational drug submitted for market approval targeting FGFR inhibitor-pretreated relapsed or refractory CCA patients. Its New Drug Application (NDA) was accepted by China's National Medical Products Administration (NMPA) in December 2025 and granted priority review, with approval expected in 2026. The confirmatory Phase III clinical study also administered its first patient dose in April 2026. Furthermore, the head of the commercialization team is already in place, with team-building progressing steadily in preparation for a potential launch.
International expansion is advancing concurrently. The global multi-center registrational Phase III clinical trial (FIRST-308) for the CCA indication announced completion of full patient enrollment on July 1st. The trial covers multiple countries and regions including the United States, European Union, United Kingdom, South Korea, and Taiwan, China. It enrolled patients with FGFR-altered advanced CCA who progressed after prior FGFR inhibitor therapy. Completing enrollment substantively validates TRANSTHERA-B's capability to execute overseas registrational clinical trials. Tingenitinib previously completed early-stage clinical trials in the US, and the management team possesses extensive overseas R&D experience. These foundations provide practical support for advancing the global multi-center Phase III registrational trial, making internationalization a natural extension of its current R&D path.
At this year's ASCO annual meeting, Professor Jun Zhou from Peking University Cancer Hospital presented data from the pivotal Phase II registrational study FIRST08. The study showed Tingenitinib achieved an objective response rate of approximately 30% and a survival benefit of 20 months after resistance to first-generation FGFR inhibitors. It also demonstrated broad-spectrum anti-cancer activity against difficult-to-treat populations, including those with FGFR point mutations. Against the backdrop of global competitors either withdrawing or stalling, the emergence of Tingenitinib provides a potential new treatment option for CCA patients facing the "no treatment available" dilemma.
Pipeline Depth and Future Potential
Beyond CCA, Tingenitinib is expanding into larger indications including prostate cancer, breast cancer, and liver cancer. In prostate cancer, it is the world's first and only investigational drug that simultaneously inhibits the FGFR/JAK pathways and has clinical efficacy evidence in metastatic castration-resistant prostate cancer (mCRPC). In May 2026, its Phase II trial combining with novel hormonal therapy (NHT) for progressed mCRPC after prior treatment received NMPA approval. Additionally, a Phase II trial combining Tingenitinib with fulvestrant for HR+/HER2- breast cancer has dosed its first patient. Phase II trials combining it with cadonilimab or ivonescimab for first-line liver cancer are also steadily progressing.
Other pipelines are advancing. TT-00973 is a novel, in-house developed AXL/FLT3 dual-target inhibitor targeting the lung cancer market, currently in Phase II. A combination therapy collaboration with Allist Pharmaceuticals has been established to enter the mainstream lung cancer赛道. TT-01488 is a novel non-covalent reversible BTK inhibitor. It has completed a Phase I trial for relapsed or refractory B-cell malignancies. On July 1st, the company announced approval to initiate a Phase II trial for this product combined with a CD20 monoclonal antibody for mantle cell lymphoma (MCL). Furthermore, pipelines like TT-01688 (an S1P1 inhibitor) and TT-01025 (an irreversible VAP-1 inhibitor) are at various clinical stages.
In November 2025, TRANSTHERA-B entered a project collaboration with US-based Neurocrine Biosciences, with considerable potential financial upside, reflecting the depth and quality of its self-developed pipeline储备. The company has also partnered with regional leaders like South Korea's LG Chem and Japan's Teijin Pharma, leveraging their local industry resources to accelerate the overseas development of several candidate drugs.
From its core product Tingenitinib to TT-00973, TT-01488, and several other investigational assets, TRANSTHERA-B remains focused on discovering and developing small-molecule innovative therapies for oncology, inflammatory, and cardiometabolic diseases, targeting globally unmet clinical needs. Since its listing one year ago, the company has achieved阶段性 progress in clinical advancement, commercialization, business development, and internationalization. The upcoming readouts of multiple Phase II data are critical validation milestones.
The recent sharp correction in the share price is attributed not only to the impact of post-lock-up liquidity but also叠加 to the overall downturn in sector sentiment and the spread of negative market情绪, rather than being solely caused by a deterioration in the company's fundamentals. Once the market digests both the liquidity discount and emotional sell-off, what remains is truly worth examining. The completion of global Phase III enrollment for Tingenitinib validates TRANSTHERA-B's global clinical operations and multinational project management capabilities. It also provides a practical reference model for the independent global expansion of domestic small-molecule innovative drugs. Subsequent value reassessment is becoming increasingly clear as clinical data are delivered one by one. Since its listing, Tingenitinib has established a preliminary布局 across multiple indications. The陆续落地 of subsequent pipeline milestones will be the key benchmark for testing this logic and warrants continued attention.
Comments